CHIH-HSIN YANG2020-05-262020-05-2620131470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878348650&doi=10.1016%2fS1470-2045%2813%2970170-0&partnerID=40&md5=3584999760ed85527d05daf7b199e2f9https://scholars.lib.ntu.edu.tw/handle/123456789/495043[SDGs]SDG3ch 5424802; crizotinib; docetaxel; pemetrexed; protein tyrosine kinase inhibitor; unclassified drug; ALK gene; brain metastasis; cancer resistance; chemotherapy induced emesis; drug dose escalation; edema; EML4 ALK oncogene; gene; gene amplification; gene mutation; gene rearrangement; gene translocation; human; letter; lung non small cell cancer; optimal drug dose; priority journal; progression free survival; visual disorder; Adenocarcinoma; Carbazoles; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gene Rearrangement; Humans; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinasesletter10.1016/S1470-2045(13)70170-0236394692-s2.0-84878348650